Abstract:
Jack Uldrich: Last Friday, I had an article on IBM's new supercomputer run in The Motley Fool. One reader questioned my choice of listing Affymetrix as a competitor. It was a fair question and I responded that because Affymetrix was involved in trying to establish genetic links to a variety of diseases for the purposes of drug discovery, I felt IBM's use of its new supercomputer to the same ends could adversely affect Affyxmetrix's business.